New names for Oxford Global’s precision medicine events bring biomarker, diagnostics, omics, pathology, data and clinical leaders together in Basel, San Diego and Boston from 2027
Oxford Global today announced new names for its precision medicine events. From 2027, they run as Precision Medicine East (Boston, 23 to 24 March 2027), Precision Medicine West (San Diego, 7 to 8 October 2027) and Precision Medicine Europe (Basel, 30 November to 1 December 2027), each with the same four interconnected programmes.
Advances in biomarkers, companion diagnostics, multi-omics, spatial biology, computational pathology and AI are transforming how medicines are developed, how clinical trials are designed and how patients are diagnosed and treated. Yet the disciplines and teams behind them often remain disconnected, even as they contribute to the same scientific and clinical decisions. Precision Medicine Europe, West and East are built to bring them together, uniting leaders from pharma, biotech, academia, diagnostics and clinical research organisations.
Each event will run four programmes:
- Biomarkers & CDx
- Computational Pathology, AI & Precision Diagnostics
- Multi-Omics Development & Applications
- AI, Data & Analysis
Alongside the programmes, the events will feature small-group discussions, the AI & Data Zone, the Startup Zone and the Partnering Programme of pre-arranged one-to-one meetings, with a Hackathon and an Investment Forum at Precision Medicine West and Precision Medicine Europe.
The new names build on more than two decades of Oxford Global’s Biomarkers and NextGen Omics events. Biomarkers, CDx & Precision Medicine Europe and NextGen Omics, Tech & Data have become Precision Medicine Europe. Biomarkers, CDx & Precision Medicine US is now Precision Medicine West, and NextGen Omics, Spatial & Data US is now Precision Medicine East.
Cerlin Roberts, CEO and Founder of Oxford Global, said: “We are seeing a fundamental shift across drug development: from individual technologies to integrated multimodal data, from scientific silos to connected decision-making, and from generating more data to delivering meaningful clinical impact. As technologies converge, so must the people. Our ambition is to break down silos between research, technology, diagnostics, drug development and clinical implementation, while keeping the scientific depth, senior-level engagement and trusted relationships our community values.”
Mike Burden, Summit Director at Oxford Global, said: “The decisions our attendees make no longer sit within one discipline. Running the same four programmes at every event means a biomarker lead in Boston, a data scientist in San Diego and a translational team in Basel can all see the wider ecosystem around their work, and meet the partners who can help them act on it.”
Between events, the community stays connected through Road to Precision Medicine, a year-round programme of free online R&D Spotlights and CEO Thought Leadership sessions.
Cerlin Roberts added: “Join us to make meaningful connections, challenge existing thinking, and help shape the future of precision medicine.”
Full details of all three events are available at https://hubs.la/Q04DW00f0




















